WORLD-CLASS SPEAKER FACULTY
Speakers
Hans-Peter Gerber
CSO
3T Biosciences
Day One
Wednesday October 27, 2021
5:00 pm | Identification of Novel pHLA Targets for Solid Tumor Targeting With Cancer Vaccines
Andres Gutierrez
Executive Vice President, CMO
Advaxis Inc
Day One
Wednesday October 27, 2021
4:00 pm | Clinical Activity & Immunogenicity of a Neoantigen Immunotherapy in Non-Small Cell Lung Cancer
Mathias Vormehr
Director Cancer Vaccines
BioNTech SE
Day Two
Thursday October 28, 2021
3:00 pm | Panel Discussion: Exploring the Best-in-Class Adjuvant to Improve Patient Response to Neoantigen Therapy
2:30 pm | Overcoming Challenges for Effective Cancer Vaccine Therapy
Jens Kringelum
Director Genomic Immuno-Oncology
Evaxion Biotech
Day One
Wednesday October 27, 2021
8:30 am | How to Use AI To Solve Bottlenecks in Neo-Epitope Identification
Ronald Plasterk
Founder, CEO
Frame Cancer Therapeutics
Day One
Wednesday October 27, 2021
1:30 pm | Whole Framome Cancer Vaccination
Chip Clark
CEO
Genocea Biosciences
Bootcamp Day
12:40 pm | Roundtable Discussion: Prioritizing Diversity, Equity & Inclusion in the Neoantigen Field
Jessica Baker Flechtner
CSO
Genocea Biosciences
Day One
Wednesday October 27, 2021
5:30 pm | Unleashing the Titans: The Gen-011 Neoantigen-Targeted Peripheral T Cell Therapy for Solid Tumors
Hubert Lam
Senior Director
Genocea Biosciences
Day One
Wednesday October 27, 2021
12:30 pm | Responses to Inhibitory Tumor Antigens, Inhibigens, Suppress Anti-Tumor Immunity & Promote Tumor Growth
Joann Peters
VP Clinical & Business Operations
Geneos Therapeutics
Bootcamp Day
12:40 pm | Roundtable Discussion: Prioritizing Diversity, Equity & Inclusion in the Neoantigen Field
Niranjan Sardesai
President & CEO, Founder
Geneos Therapeutics
Bootcamp Day
10:50 am | Panel Discussion: Examining the Impact of the Pandemic on Global Supply Chain to Gain Insight Into Next Strategy Steps
Day Two
Thursday October 28, 2021
11:00 am | Industry Leader’s Fireside Chat
10:30 am | Personalized Cancer Vaccine for Treating Patients With Advanced Hepatocellular Cancer
Day One
Wednesday October 27, 2021
1:00 pm | Targeting ERAP1: Altering Neoantigen Presentation With a Small Molecule
Andrew Allen
CEO
Gritstone Bio
Day Two
Thursday October 28, 2021
11:00 am | Industry Leader’s Fireside Chat
9:30 am | Now It Gets Real- Clinical Data in Advanced Cancer Patients Treated With an Individualized Neoantigen Vaccine
Karin Jooss
Head of R&D
Gritstone Bio
Day One
Wednesday October 27, 2021
3:30 pm | Development of Shared Neoantigen Vaccines for Off-the-Shelf Cancer Therapy
Julia Kodysh
Senior Scientist, Computational Research
Icahn School of Medicine, Mount Sinai
Day One
Wednesday October 27, 2021
9:00 am | Utilizing Novel Computational Techniques to Select Effective & Globally Expressed Neoantigens
Alex Karlsson-Parra
CEO
Immunicum AB
Day Two
Thursday October 28, 2021
3:00 pm | Panel Discussion: Exploring the Best-in-Class Adjuvant to Improve Patient Response to Neoantigen Therapy
2:00 pm | The Adjuvant Part of Neoantigen Cancer Vaccines: No Clear Winner Has Yet Emerged
Stephen Schoenberger
Professor
La Jolla Institute for Immunology
Dolores J. Schendel
CEO & CSO
Medigene AG
Day One
Wednesday October 27, 2021
11:30 am | Dark Matter Antigens: Exploration With Molecular & Cellular Tools
Elisa Scarselli
Co-Founder, CSO
Nouscom
Day Two
Thursday October 28, 2021
2:30 pm | Nouscom Genetic Vaccine Encoding Shared Neoantigens to Treat Tumors with MicroSatellite Instability (MSI)
Eric Halioua
President & CEO
PDC*line Pharma
Bootcamp Day
10:50 am | Panel Discussion: Examining the Impact of the Pandemic on Global Supply Chain to Gain Insight Into Next Strategy Steps
Day One
Wednesday October 27, 2021
3:00 pm | New Class of Antigen-Specific Cancer Active Immunotherapies Based on an Off-the-Shelf Antigen Presenting Cell Line (PDC*line)
Philip M Arlen
President & CEO
Precision Biologics, Inc
Day Two
Thursday October 28, 2021
12:30 pm | Developing mab Therapies From Tumor Neoantigens
Massimo Fantini
Senior Scientist
Precision Biologics, Inc.
Bootcamp Day
11:50 am | Stability Tests to Monitor the Shelf Life Of Monoclonal Antibodies Employed in Cancer Immunotherapy
Christopher Gallen
Chairman & CEO
Treos Bio Ltd
Day Two
Thursday October 28, 2021
10:00 am | Treos’ Novel & Potentially Transformative Big Data Approach to Increasing the Effectiveness of Cancer Vaccines by Incorporating a Systematic Understanding of Antigen Targets & HLA Responses
Eli Gilboa
Professor of Immunology & Microbiology
University of Miami
Agnete Fredriksen
Chief Innovation & Strategy Officer
Vaccibody As
Day Two
Thursday October 28, 2021
5:00 pm | Targeting Antigens to Antigen Presenting Cells To Create More Efficacious Vaccines
4:00 pm | Panel Discussion: Reviewing Lessons Learnt From the Pandemic to Inform the Future of Cancer Therapy
Paul Higham
CEO
Valo Therapeutics
Day Two
Thursday October 28, 2021
4:30 pm | PeptiVAX, a Vaccine Platform for Flexibly Targeting New & Emerging Infectious Disease
4:00 pm | Panel Discussion: Reviewing Lessons Learnt From the Pandemic to Inform the Future of Cancer Therapy
Sari Pesonen
Head R&D
Valo Therapeutics
Day One
Wednesday October 27, 2021
10:00 am | PeptiCRAd, a Platform for Neoantigen Vaccine Delivery in Cancer
Albrecht Meichle
VP Regulatory Affairs & CMC
Vaximm
Bootcamp Day
10:50 am | Panel Discussion: Examining the Impact of the Pandemic on Global Supply Chain to Gain Insight Into Next Strategy Steps
10:30 am | Break Out Audience Discussion
Heinz Lubenau
CEO & Co-Founder
Vaximm
Day Two
Thursday October 28, 2021
12:00 pm | Optimizing Patient Selection & Stratification to Improve Success in Clinical Trials
